Lexicon Pharmaceuticals Share Price (NASDAQ: LXRX)

$1.17

▲

-0.02

(-1.68%)

Live

Last updated on August 26, 2025 at 12:40 AM IST

$₹

Check the interactive Lexicon Pharmaceuticals Stock chart to analyse performance

Lexicon Pharmaceuticals stock performance

as on August 26, 2025 at 12:40 AM IST

Today's Low:$1.17
Today's High:$1.19
$1.17
0.0%
Downside
Day's Volatility :1.68%
Upside
1.68%
52 Weeks Low:$0.28
52 Weeks High:$2.18
$1.17
75.76%
Downside
52 Weeks Volatility :86.96%
Upside
46.21%

Lexicon Pharmaceuticals Stock Returns

Period	Lexicon Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	72.46%	6.0%	0.0%
6 Months	69.47%	-7.2%	0.0%
1 Year	-32.77%	-11.1%	0.0%
3 Years	-57.35%	5.5%	-10.0%

Lexicon Pharmaceuticals, Inc. Key Stats

Check Lexicon Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.19
Open	$1.175
Today's High	$1.19
Today's Low	$1.15
Market Capitalization	$432.4M
Today's Volume	$1.4M
52 Week High	$2.175
52 Week Low	$0.2836
Revenue TTM	$58.4M
EBITDA	$-105.5M
Earnings Per Share (EPS)	$-0.32
Profit Margin	-206.43%
Quarterly Earnings Growth YOY	-0.63%
Return On Equity TTM	-65.3%

Stock Returns calculator for Lexicon Pharmaceuticals Stock including INR - Dollar returns

The Lexicon Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Lexicon Pharmaceuticals investment value today

Current value as on today

₹70,437

Returns

₹29,563

(-29.56%)

Returns from Lexicon Pharmaceuticals Stock

₹33,898 (-33.9%)

Dollar Returns*

₹4,335 (+4.33%)

Indian investors sentiment towards Lexicon Pharmaceuticals Stock

-56%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Lexicon Pharmaceuticals Stock from India on INDmoney has decreased by -56% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Lexicon Pharmaceuticals, Inc.

Name
Holdings %
Name
Holdings %
Artal Group S A
37.47%
Siren, L.L.C.
10.71%
FMR Inc
9.51%
BlackRock Inc
2.76%
Vanguard Group Inc
2.44%
Schonfeld Strategic Advisors LLC
1.26%

Analyst Recommendation on Lexicon Pharmaceuticals Stock

Rating

Trend

Buy

72%Buy

27%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Lexicon Pharmaceuticals(by analysts ranked 0 to 5 stars)

Lexicon Pharmaceuticals Share Price Target

What analysts predicted

Upside of 135.04%

Target:

$2.75

Current:

$1.17

Lexicon Pharmaceuticals share price target is $2.75, a slight Upside of 135.04% compared to current price of $1.17 as per analysts' prediction.

Lexicon Pharmaceuticals Stock Insights

Price Movement
In the last 3 months, LXRX stock has moved up by 80.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.26M → 28.86M (in $), with an average increase of 95.6% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -64.81M → 3.25M (in $), with an average increase of 334.4% per quarter
LXRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 101.7%
LXRX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 172.7%
Price to Sales
ForLXRX every $1 of sales, investors are willing to pay $7.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Lexicon Pharmaceuticals, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$322.1M	↑ 409.54%
Net Income	$130.1M	↓ 207.95%
Net Profit Margin	40.4%	↑ 231.11%

	FY20	Y/Y Change
Revenue	$24.0M	↓ 92.55%
Net Income	$-70.2M	↓ 153.93%
Net Profit Margin	-292.49%	↓ 332.89%

	FY21	Y/Y Change
Revenue	$298.0K	↓ 98.76%
Net Income	$-88.3M	↑ 25.77%
Net Profit Margin	-29.6K%	↓ 29327.64%

	FY22	Y/Y Change
Revenue	$139.0K	↓ 53.36%
Net Income	$-103.1M	↑ 16.84%
Net Profit Margin	-74.2K%	↓ 44572.68%

	FY23	Y/Y Change
Revenue	$1.2M	↑ 766.19%
Net Income	$-177.1M	↑ 71.75%
Net Profit Margin	-14.7K%	↑ 59481.93%

	FY24	Y/Y Change
Revenue	$31.1M	↑ 2481.48%
Net Income	$-200.4M	↑ 13.15%
Net Profit Margin	-644.78%	↑ 14066.1%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.1M	↑ 60.97%
Net Income	$-48.4M	↑ 0.32%
Net Profit Margin	-4.3K%	↑ 2589.44%

	Q2 FY24	Q/Q Change
Revenue	$1.6M	↑ 45.75%
Net Income	$-53.4M	↑ 10.4%
Net Profit Margin	-3.2K%	↑ 1038.9%

	Q3 FY24	Q/Q Change
Revenue	$1.8M	↑ 6.25%
Net Income	$-64.8M	↑ 21.3%
Net Profit Margin	-3.7K%	↓ 459.47%

	Q4 FY24	Q/Q Change
Revenue	$26.6M	↑ 1417.37%
Net Income	$-33.8M	↓ 47.9%
Net Profit Margin	-127.16%	↑ 3576.33%

	Q1 FY25	Q/Q Change
Revenue	$1.3M	↓ 95.25%
Net Income	$-25.3M	↓ 25.09%
Net Profit Margin	-2.0K%	↓ 1877.2%

	Q2 FY25	Q/Q Change
Revenue	$28.9M	↑ 2187.32%
Net Income	$3.3M	↓ 112.86%
Net Profit Margin	11.27%	↑ 2015.63%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$318.8M	↑ 425.12%

	FY20	Y/Y Change
Profit	$22.1M	↓ 93.08%

	FY21	Y/Y Change
Profit	$-54.7M	↓ 348.11%

	FY22	Y/Y Change
Profit	$-288.0K	↓ 99.47%

	FY23	Y/Y Change
Profit	$1.1M	↓ 488.54%

	FY24	Y/Y Change
Profit	$30.5M	↑ 2622.52%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$955.0K	↑ 96.91%

	Q2 FY24	Q/Q Change
Profit	$1.5M	↑ 55.08%

	Q3 FY24	Q/Q Change
Profit	$1.7M	↑ 13.37%

	Q4 FY24	Q/Q Change
Profit	$26.2M	↑ 1460.81%

	Q1 FY25	Q/Q Change
Profit	$1.2M	↓ 95.3%

	Q2 FY25	Q/Q Change
Profit	$28.7M	↑ 2226.06%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$113.8M	↓ 176.58%
Investing Cash Flow	$-155.9M	↓ 191.91%
Financing Cash Flow	$-2.2M	↓ 0.8%

	FY20	Y/Y Change
Operating Cash Flow	$-143.0M	↓ 225.62%
Investing Cash Flow	$380.8M	↓ 344.3%
Financing Cash Flow	$-147.6M	↑ 6532.35%

	FY21	Y/Y Change
Operating Cash Flow	$-87.0M	↓ 39.14%
Investing Cash Flow	$2.1M	↓ 99.45%
Financing Cash Flow	$22.7M	↓ 115.38%

	FY22	Y/Y Change
Operating Cash Flow	$-88.9M	↑ 2.11%
Investing Cash Flow	$-71.1M	↓ 3468.63%
Financing Cash Flow	$142.2M	↑ 526.22%

	FY23	Y/Y Change
Operating Cash Flow	$-161.9M	↑ 82.21%
Investing Cash Flow	$-49.9M	↓ 29.73%
Financing Cash Flow	$188.0M	↑ 32.17%

	FY24	Y/Y Change
Operating Cash Flow	$-178.8M	↑ 10.43%
Investing Cash Flow	$-15.4M	↓ 69.21%
Financing Cash Flow	$238.3M	↑ 26.81%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-55.1M	↑ 9.06%
Investing Cash Flow	$-110.2M	↓ 312.39%
Financing Cash Flow	$239.4M	↓ 2.39384E7%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-48.5M	↓ 11.95%
Investing Cash Flow	$-12.3M	↓ 88.82%
Financing Cash Flow	$-14.0K	↓ 100.01%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-53.6M	↑ 10.46%
Investing Cash Flow	$53.5M	↓ 533.9%
Financing Cash Flow	$-916.0K	↑ 6442.86%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-21.5M	↓ 59.92%
Investing Cash Flow	$53.7M	↑ 0.43%
Financing Cash Flow	$-104.0K	↓ 88.65%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-43.8M	↑ 103.7%
Investing Cash Flow	$40.6M	↓ 24.43%
Financing Cash Flow	$-572.0K	↑ 450.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$17.0M	↓ 138.82%
Investing Cash Flow	$15.5M	↓ 61.85%
Financing Cash Flow	$-45.0M	↑ 7767.13%

Lexicon Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Lexicon Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Lexicon Pharmaceuticals, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lexicon Pharmaceuticals, Inc.	9.17%	69.47%	-32.77%	-57.35%	-33.15%
Regeneron Pharmaceuticals, Inc.	5.52%	-17.35%	-50.85%	-1.12%	-3.68%
Beone Medicines Ltd	6.51%	21.35%	57.45%	73.21%	25.84%
Vertex Pharmaceuticals Incorporated	-14.26%	-17.97%	-18.13%	40.27%	45.64%
Alnylam Pharmaceuticals, Inc.	39.9%	82.53%	68.83%	115.41%	241.51%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lexicon Pharmaceuticals, Inc.	NA	NA	-0.14	-0.19	-0.65	-0.22	NA	0.36
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.08	28.08	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lexicon Pharmaceuticals, Inc.	Buy	$432.4M	-33.15%	NA	-206.43%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-3.68%	14.86	31.37%
Beone Medicines Ltd	NA	$38.3B	25.84%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.3B	45.64%	28.08	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.6B	241.51%	NA	-12.96%

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Organization	Lexicon Pharmaceuticals
Employees	103
CEO	Dr. Michael S. Exton Ph.D.
Industry	Health Technology

Key Management of Lexicon Pharmaceuticals, Inc.

Name	Title
Dr. Michael S. Exton Ph.D.	CEO & Director
Ms. Kristen L. Alexander	Vice President of Finance & Accounting
Mr. Brian T. Crum	Senior VP, General Counsel & Secretary
Dr. Craig B. Granowitz M.D., Ph.D.	Senior VP & Chief Medical Officer
Mr. Scott M. Coiante	Senior VP & CFO
Ms. Lisa M. DeFrancesco	Senior Vice President of Investor Relations & Corporate Communications
Mr. Dixon Terry	Vice President of Compliance
Ms. Carrie Siragusa	Vice President of Marketing
Ms. Desiree Gendron	Vice President of Sales & Training
Ms. Wendy E. McDermott	Senior Vice President of Human Resources

Important FAQs about investing in LXRX Stock from India :

What is Lexicon Pharmaceuticals share price today?

Lexicon Pharmaceuticals share price today is $1.17 as on August 26, 2025 at 12:40 AM IST. Lexicon Pharmaceuticals share today touched a day high of $1.19 and a low of $1.17.

What is the 52 week high and 52 week low for Lexicon Pharmaceuticals share?

Lexicon Pharmaceuticals share touched a 52 week high of $2.18 and a 52 week low of $0.28. Lexicon Pharmaceuticals stock price today i.e. August 26, 2025 at 12:40 AM IST is trending at $1.17, lower by 46.21% versus the 52 week high.

How to invest in Lexicon Pharmaceuticals Stock (LXRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Lexicon Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lexicon Pharmaceuticals Shares that will get you 1.2821 shares as per Lexicon Pharmaceuticals share price of $1.17 per share as on August 26, 2025 at 12:40 AM IST.

What is the minimum amount required to buy Lexicon Pharmaceuticals Stock (LXRX) from India?

Indian investors can start investing in Lexicon Pharmaceuticals (LXRX) shares with as little as ₹87.537 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.37 in Lexicon Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Lexicon Pharmaceuticals share’s latest price of $1.17 as on August 26, 2025 at 12:40 AM IST, you will get 8.5470 shares of Lexicon Pharmaceuticals. Learn more about fractional shares .

What are the returns that Lexicon Pharmaceuticals has given to Indian investors in the last 5 years?

Lexicon Pharmaceuticals stock has given -33.15% share price returns and 18.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Direxion Dy Csco Bear 1x Etf
$24.50
+1.58%
Bny Mellon Concentrated Intl
$51.00
+0.06%
Orion Energy Systems Inc
$6.75
+8.7%
Tradr 1.5x Short Nvda Daily Etf
$11.91
-0.75%
Venus Concept Inc
$2.42
-1.22%
Virtus Real Asset Income Etf
$23.86
+2.49%
Landmark Bancorp Inc
$26.24
-2.2%
Central Puerto Sa
$10.75
-2.45%
First Trust Flexible Municipal High Income Etf
$16.42
-0.12%

Explore all

Lexicon Pharmaceuticals Share Price (NASDAQ: LXRX)

Lexicon Pharmaceuticals stock performance

Lexicon Pharmaceuticals Stock Returns

Lexicon Pharmaceuticals, Inc. Key Stats

Stock Returns calculator for Lexicon Pharmaceuticals Stock including INR - Dollar returns

Indian investors sentiment towards Lexicon Pharmaceuticals Stock

Global Institutional Holdings in Lexicon Pharmaceuticals, Inc.

Analyst Recommendation on Lexicon Pharmaceuticals Stock

Lexicon Pharmaceuticals Share Price Target

Lexicon Pharmaceuticals Stock Insights

Price Movement

Increasing Revenue

Increasing Net Profit

LXRX vs ALNY (1 yr)

LXRX vs ALNY (3 yr)

Price to Sales

Lexicon Pharmaceuticals, Inc. Financials

Lexicon Pharmaceuticals Technicals Summary

Lexicon Pharmaceuticals, Inc. Vs Peers

About Lexicon Pharmaceuticals, Inc.

Key Management of Lexicon Pharmaceuticals, Inc.

Important FAQs about investing in LXRX Stock from India :

What is Lexicon Pharmaceuticals share price today?

What is the 52 week high and 52 week low for Lexicon Pharmaceuticals share?

How to invest in Lexicon Pharmaceuticals Stock (LXRX) from India?

What is the minimum amount required to buy Lexicon Pharmaceuticals Stock (LXRX) from India?

What are the returns that Lexicon Pharmaceuticals has given to Indian investors in the last 5 years?

Discover More